UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therapeutics, one of the leading T cell engager companies. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the $2 billion takeout and the opportunity in the TCE space.
They also assess the drug development landscape for leukodystrophies and the market for biotech IPOs on NASDAQ, where a trio of biotechs exceeded expectations last week, lifting hopes that the window for new listings is broadening. Looking ahead to June, the analysts also preview the third BioCentury Grand Rounds U.S. conference. This episode of the BioCentury This Week podcast was brought to you by Jeito Capital.

View full story: https://www.biocentury.com/article/659365

#BiotechMA #TCellEngagers #Leukodystrophy #BiotechIPO #TranslationalScience

00:01 - Sponsor Message: Jeito Capital
02:19 - Grand Rounds Seattle
12:47 - UCB’s Candid Buy
20:27 - Leukodystrophies Pipeline
27:22 - Biotech IPOs

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text